SGLT-2 Inhibitors Tied to Lower Risk for Autoimmune Rheumatic Diseases in Adults With T2D
Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are associated with a reduced risk for autoimmune rheumatic diseases.
According to a study,
SGLT-2 inhibitors are associated with a reduced risk for autoimmune rheumatic diseases compared with sulfonylureas among adults with type 2 diabetes.
Researchers from Sungkyunkwan University in the Republic of Korea, led by Bin Hong, conducted a retrospective cohort study involving 2,032,157 adults with type 2 diabetes.
- The study included 1,030,088 SGLT-2 inhibitor initiators and 1,002,069 sulfonylurea initiators after propensity score weighting.
- The weighted incidence rate was 51.90 and 58.41 per 100,000 person-years in individuals initiating SGLT-2 inhibitors and sulfonylureas, respectively.
Author's summary: SGLT-2 inhibitors reduce autoimmune disease risk.
More News
- Winnebago Lutheran's Gannan Schwartz highlights Level 1 action with 287 rush yards, 4 TDs
- Why Hiring a Fishers Personal Injury Lawyer Is Key After a Car Accident, Slip, or Dog Bite | NorthPennNow
- Landmark New Report Shows Canadian Lobbyists Represent Major Polluters Alongside Environmental Groups
- Man Utd Failed With £50 Million Mbeumo Alternative
- How to Choose and Install the Right Bathroom Ventilation System | NorthPennNow
- Renters Rights Bill becomes law - Letting Agent Today
- Sweden’s still ahead in the preparedness game — and now it means business
- READY, FIRE, AIM: Fly Me to the Moon – Pagosa Daily Post News Events & Video for Pagosa Springs Colorado
- Battlefield 6 REDSEC battle royale to officially launch soon
- Three resilient UK multinationals global managers are excited about | Trustnet